Muutke küpsiste eelistusi

E-raamat: Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications

Edited by , Edited by , Edited by
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 221,68 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Reactive Oxygen Species: Network Pharmacology and Therapeutic ApplicationsSuurem pilt
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term ‘oxidative stress’ is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology.  

Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.  


Part I: ROS Revisited: Changing the Focus from Oxidative Stress and
Redox Biology to Redox Medicine.- Demystifying oxidative stress.- Oxidants in
Physiological Processes.- Network Medicine-Based Unbiased Disease Modules for
Drug and Diagnostic Target Identification in ROSopathies.- Part II Targeting
antioxidant responses.- Development of Telintra as an Inhibitor of
Glutathione S-Transferase P.- Perspectives on the Clinical Development of
NRF2-Targeting Drugs.- Part III: Inhibiting ROS formation and toxification.-
NOX Inhibitors: From Bench to Naxibs to Bedside.- Nitric Oxide Synthase
Inhibitors into the Clinic at Last.- Xanthine Oxidoreductase Inhibitors.-
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.-
Inhibition of Myeloperoxidase.- Part IV: Stimulating/substituting ROS.-
Effects of Mammalian Thioredoxin Reductase Inhibitors.- Cardiovascular
Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO) and Nitroxyl
(HNO), in the Setting of Reactive Oxygen Species Dysregulation.-
Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers.- Part V: Repairing
ROS damage.- Soluble Guanylate Cyclase Stimulators and Activators Peter
Sander.- Inhibitors of Advanced Glycation End Product (AGE) Formation and
Accumulation.
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97830306851026e.html
Märksõnad: